Commercial Payer 340B Reimbursement Policy Changes

The 340B program pays covered entities through a simple mechanism: buy drugs at a steep discount, bill payers at market rates, and keep the difference. That difference is called spread, and how big it gets depends almost entirely on who's paying the bill. Congress created the program in 1992 to give safety-net providers access to discounted outpatient drugs, after the Medicaid best-price rule had an unintended side effect: manufacturers started pulling back from voluntary discount deals because those deals were triggering even bigger required rebates under Medicaid. 340B was the fix, built to make sure safety-net hospitals and clinics could still afford the drugs their patients needed.

The program's growth since then tells its own story. What began as a modest subsidy for safety-net providers is now the second-largest drug-purchasing program in the country. Purchases reached $66.3 billion in 2023, a sharp jump from prior years, when you look at USC Schaeffer's analysis of the program. But the growth isn't evenly distributed. USC Schaeffer's research shows that how much revenue a covered entity can pull from 340B tracks closely with its share of commercially insured patients. Hospitals draw most of their 340B net revenue from commercial payers, but non-hospital federal grantees, the clinics closer to the program's original safety-net mission, draw much less.

That detail explains who has the most riding on this program. Infusion centers and buy-and-bill specialty practices with strong commercial payer panels have built real financial stability on 340B spread over the years. They're also the ones most exposed the moment commercial reimbursement terms shift, because their margin was never really coming from Medicare. It was coming from the gap between what they paid for a drug and what a commercial plan reimbursed for it. That gap is the whole financial engine behind this corner of the program, and it's the thing now coming under pressure from every direction.

What CMS is proposing for Medicare 340B reimbursement

CMS has proposed cutting Medicare reimbursement for 340B-acquired drugs from ASP plus 6% down to ASP minus 33.4%. That's the most consequential federal reimbursement signal in the program's 30-plus year history, and commercial payers are reading it closely as a benchmark for their own contracts. The shift is already partway underway. The CY 2026 OPPS Final Rule, summarized by IHA in December 2025, applied a 0.5 percentage point annual reduction to the OPPS conversion factor as part of an ongoing 340B remedy offset. The mechanism is already running, and CMS has proposed a much larger cut for 2027.

The legal footing behind this proposal matters as much as the number itself. In 2022, the Supreme Court struck down an earlier ASP-minus cut in American Hospital Association v. Becerra, ruling that CMS had never conducted the acquisition cost survey required before making that kind of change. CMS has closed that gap this time. The CY 2027 proposal rests on a survey conducted between January 1 and April 7, 2026, built specifically to satisfy the requirement the Court laid out. That makes this cut far harder to challenge in court than the one it replaces.

For infusion practices, the Medicare rate itself isn't the headline. For infusion practices, the signal matters because Medicare is establishing, with legal backing this time, that 340B spread is a legitimate target for reimbursement policy. Commercial payers take their cues from exactly that kind of federal framing, and the next section shows how they're already acting on it.

How commercial payers are independently tightening 340B reimbursement terms

Commercial payers aren't waiting on CMS to finish its rulemaking; they're running their own parallel strategy to shrink 340B spread through two channels: tightening contract pharmacy terms and pushing site-of-care policies that quietly redirect infusion volume away from 340B-eligible settings. USC Schaeffer's research names commercial spread as the main revenue mechanism for 340B entities, and it finds that reform pressure aimed at that spread is building across every type of payer, not just Medicare.

Site-of-care programs are the clearest example of how this works in practice. Instead of changing a reimbursement rate directly, a payer steers infusion patients toward ambulatory infusion suites or home infusion. When a patient gets redirected that way, the drug never gets purchased through a 340B account and billed at commercial rates. The spread shrinks because the volume moved, not because the rate changed. It's a quieter lever than a rate cut, but the effect on a hospital's 340B revenue is the same direction: down.

Payers also have a policy argument backing this behavior, and it's one borrowed almost directly from USC Schaeffer's research: wealthier hospitals with larger commercially insured patient bases are the ones benefiting most from 340B spread, often disproportionately relative to the program's safety-net mission. Commercial payers are using that argument actively in contract renegotiations. The obvious pushback is that payers can't unilaterally reprice a 340B-acquired drug the way CMS can through rulemaking. They don't need to. Site-of-care redirection, prior authorization friction, and contract pharmacy restrictions all achieve roughly the same outcome by cutting the number of transactions where spread is even possible.

Rebate model pilot cash-flow mechanics for infusion revenue cycles

A separate change out of HRSA is reshaping how 340B transactions actually move money, and it hits cash flow in a way the rate conversation doesn't touch. HRSA published a revised 340B Rebate Model Pilot Program on August 3, 2026. Under the pilot, covered entities buy a subset of drugs at wholesale acquisition cost (WAC), the full, undiscounted price, up front. They then submit claims to manufacturers after the drug has already been dispensed, and the manufacturer sends back a rebate: WAC minus the 340B ceiling price.

This isn't the first version of this idea. HRSA announced an earlier pilot on July 31, 2025, and it set a planned start date of January 1, 2026. A federal district court vacated that version in February 2026 because it failed to follow required rulemaking procedures. The August 2026 revision is HRSA's rebuilt version of the same concept, now reconstituted to address that ruling.

The operational consequence is the part infusion revenue cycle teams need to plan around. Under the old model, the discount came first: a covered entity paid the discounted price at the point of purchase, and the spread was baked in from day one. Under the rebate model, the practice has to fund the full WAC-level cost out of its own working capital and wait for the manufacturer to send the rebate back after the fact. That's a real float problem. Drug acquisition on infusion biologics isn't cheap, and fronting the full price on a subset of transactions, then waiting on a separate rebate receivable, means new claims workflows, tighter reconciliation discipline, and an entirely new category of AR to track that sits apart from the payer claim itself.

Compounding reform pressure, federal, commercial, and manufacturer, as a lasting shift

Three separate pressure sources are converging on the same target at the same time. Federal rulemaking is cutting the Medicare rate and tightening the cash-flow mechanics through the rebate pilot. Commercial payers are compressing spread through site-of-care steering and contract renegotiation. Manufacturers are adding contract pharmacy restrictions on top of both. None of these three is reacting to the others in a coordinated way, but all three point in the same direction, and bipartisan interest in broader 340B reform in Congress suggests none of them is likely to reverse.

USC Schaeffer's research lays out the structural reform argument directly: meaningful reform that removes the market distortions 340B has created requires removing spread pricing as the revenue mechanism, or at minimum changing how 340B revenues get distributed once they're captured. Either path cuts into the margin infusion centers have relied on. And the legal ground has shifted under hospitals' feet. The CY 2027 proposal was built specifically to fix the survey deficiency the Supreme Court flagged in 2022, so the legal defense that protected hospitals from the 2018 ASP-minus cut doesn't apply the same way this time.

States are adding a third layer on top of the federal and commercial pressure. Some states are expanding contract pharmacy access protections for 340B entities, but at the same time they're imposing new reporting and transparency requirements on those same entities. That combination doesn't ease the financial pressure, it adds a compliance burden next to it. None of this points to a specific final number or a guaranteed outcome. What it shows is a direction already in motion across three independent levers, federal, commercial, and manufacturer, all moving the same way at once.

J-code billing accuracy and modifier discipline in buy-and-bill infusion practices

All of this policy pressure eventually lands on a single claim form. J-code accuracy and modifier discipline are where 340B spread gets captured or lost, one claim at a time. As CMS and commercial payers both scrutinize 340B billing more closely, errors that were always costly now carry sharper consequences: denials and audit exposure that a compressed margin has no room left to absorb.

Every claim for a 340B-acquired drug needs the correct modifier, and every claim for a non-340B drug needs its own corresponding modifier. That tracking has to hold up through every authorization cycle, every dose adjustment, and every biosimilar substitution, without a single gap. Drug waste carries its own modifier requirement too. If you leave it off when waste actually occurred, the claim creates underbilling risk or a payer dispute down the line, and that risk grows as payers put more scrutiny on individual 340B claim lines.

Code maintenance adds another failure point. Effective January 1, 2026, claims billed with newly discontinued HCPCS codes get rejected. CMS has held this no-grace-period policy since January 1, 2010, so there's nothing new about the rule, but the removal of any informal grace period means billing systems and charge masters have to be updated on a quarterly cycle or practices face automatic denials on 340B-flagged claims. The buy-and-bill model makes all of this higher stakes than it looks on paper. If a claim on a high-cost biologic gets denied, the practice holds the full acquisition cost and gets zero reimbursement back. Given the drug costs involved in infusion therapy, a single unit-count error on a high-dose claim can produce a material underpayment on that one claim alone.

Prior authorization management as a 340B preservation strategy

The claim-level problems above usually start much earlier, at the authorization stage. As commercial payers add more prior authorization friction around high-cost biologics, infusion centers managing authorization reactively, waiting until something lapses to react, are exposed to mid-treatment gaps that break the 340B billing chain and trigger denials on claims that had almost no margin to begin with.

The site-of-care programs described earlier often run through authorization policy directly. A payer requires authorization for a lower-cost site before it will approve hospital outpatient infusion. That means an authorization denial and a site-of-care denial are, functionally, the same problem wearing two different names. Authorization management has to start before the treatment cycle begins, not after a lapse causes a denial. For a recurring infusion regimen on a biologic, an authorization that lapses mid-cycle produces a denied claim on a drug that's already been purchased. That creates an AR problem and a cash-flow problem at the exact same moment. Biosimilar substitutions make this worse. Payers increasingly push these substitutions, and each one requires re-authorization under a new J-code. If the billing team doesn't catch the switch in time, the modifier chain breaks, because the modifier has to follow the drug actually dispensed, not the drug originally authorized.

Building a proactive authorization process costs staffing time and workflow investment. But if a biologic claim gets denied, at today's acquisition costs it ties up far more cash than a structured authorization tracking process would ever cost to run. By the time a claim reaches submission, the denial it triggers was usually caused earlier, by a lapse at scheduling and authorization, long before billing ever touches it.

Infusion AR management amid compressing 340B spread and rising denial rates

Spread is narrowing and denial pressure is rising at the same time, and that combination is what separates practices that hold their margin from practices that don't. The ones that hold it build AR management around payer-specific tracking, line-level remittance reconciliation, and aging prioritization by dollar value, not around sheer billing throughput.

Underpayments on 340B drug claims carry their own specific risk. A commercial payer can pay at a rate that doesn't match the contracted ASP-plus rate for a 340B-acquired drug, and without a line-level review of the remittance, that discrepancy just gets accepted as final. Multiplied across volume, that discrepancy becomes a steady write-off. The 835 remittance is the main tool for catching both underpayments and denials, since the CARC and RARC codes attached to it identify the adjustment reason and the specific remark behind it. Skipping that review at the drug-line level causes a revenue cycle team to chase symptoms while the actual cause goes unaddressed.

Denial patterns in 340B-related infusion claims aren't one problem, so you need a different fix for each one. A site-of-care denial from one payer, a modifier error denial from another, and an authorization lapse denial from a third each need a different resolution path. Treating them as one generic denial bucket buries the signal a practice needs to stop them from recurring.

The infusion revenue cycle operations that keep days in AR low and denial rates under benchmark don't get there by adding billing headcount. They get there with structured exception analytics that flag at-risk claims both before and after submission, paired with payer-specific escalation paths and real follow-up discipline that someone actually tracks. That's the operating model infusion-specialized revenue cycle platforms are built around: software that tracks authorization status, modifier assignments, and remittance exceptions, combined with people who make the judgment calls no rules engine can make on its own, giving practice leaders visibility into outcomes. Under this kind of margin pressure, a general-purpose billing tool that wasn't built around infusion's specific mechanics, modifiers, J-codes, authorization chains, 340B flags, creates revenue loss that's entirely predictable, and entirely preventable.